2-AminofluoreneCAS# 153-78-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 153-78-6 | SDF | Download SDF |
PubChem ID | 1539 | Appearance | Powder |
Formula | C13H11N | M.Wt | 181 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 9H-fluoren-2-amine | ||
SMILES | C1C2=CC=CC=C2C3=C1C=C(C=C3)N | ||
Standard InChIKey | CFRFHWQYWJMEJN-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C13H11N/c14-11-5-6-13-10(8-11)7-9-3-1-2-4-12(9)13/h1-6,8H,7,14H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
2-Aminofluorene Dilution Calculator
2-Aminofluorene Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.5249 mL | 27.6243 mL | 55.2486 mL | 110.4972 mL | 138.1215 mL |
5 mM | 1.105 mL | 5.5249 mL | 11.0497 mL | 22.0994 mL | 27.6243 mL |
10 mM | 0.5525 mL | 2.7624 mL | 5.5249 mL | 11.0497 mL | 13.8122 mL |
50 mM | 0.1105 mL | 0.5525 mL | 1.105 mL | 2.2099 mL | 2.7624 mL |
100 mM | 0.0552 mL | 0.2762 mL | 0.5525 mL | 1.105 mL | 1.3812 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Rutin
Catalog No.:BCN1684
CAS No.:153-18-4
- Guajadial F
Catalog No.:BCN6437
CAS No.:1529775-08-3
- Guajadial E
Catalog No.:BCN7754
CAS No.:1529775-06-1
- Guajadial D
Catalog No.:BCN7756
CAS No.:1529775-04-9
- Guajadial C
Catalog No.:BCN7755
CAS No.:1529775-02-7
- Dehydro-alpha-lapachone
Catalog No.:BCN1683
CAS No.:15297-92-4
- Nolatrexed (AG-337)
Catalog No.:BCC6430
CAS No.:152946-68-4
- Ginkgolide M
Catalog No.:BCC8178
CAS No.:15291-78-8
- Ginkgolide B
Catalog No.:BCN1682
CAS No.:15291-77-7
- Ginkgolide C
Catalog No.:BCN1681
CAS No.:15291-76-6
- Ginkgolide A
Catalog No.:BCN1680
CAS No.:15291-75-5
- Chartarlactam A
Catalog No.:BCN7110
CAS No.:1528745-88-1
- H-D-Trp-OH
Catalog No.:BCC3117
CAS No.:153-94-6
- Serotonin HCl
Catalog No.:BCC4715
CAS No.:153-98-0
- Precursor of cefcapene diisopropylanmine salt
Catalog No.:BCC9127
CAS No.:153012-37-4
- SR 140333
Catalog No.:BCC6098
CAS No.:153050-21-6
- Diclofenac Sodium
Catalog No.:BCC4439
CAS No.:15307-79-6
- Diclofenac
Catalog No.:BCC5249
CAS No.:15307-86-5
- N-Methyltaxol C
Catalog No.:BCN7343
CAS No.:153083-53-5
- Thiamphenicol
Catalog No.:BCC4736
CAS No.:15318-45-3
- Taxayunnansin A
Catalog No.:BCN1685
CAS No.:153229-31-3
- Cilomilast
Catalog No.:BCC2283
CAS No.:153259-65-5
- ML355
Catalog No.:BCC8060
CAS No.:1532593-30-8
- 4,4'-Bis(2-benzoxazolyl)stilbene
Catalog No.:BCC8656
CAS No.:1533-45-5
High-Affinity Low-Capacity and Low-Affinity High-Capacity N-Acetyl-2-Aminofluorene (AAF) Macromolecular Binding Sites Are Revealed During the Growth Cycle of Adult Rat Hepatocytes in Primary Culture.[Pubmed:29319817]
Toxicol Sci. 2018 May 1;163(1):35-44.
Long-term cultures of primary adult rat hepatocytes were used to study the effects of N-acetyl-2-Aminofluorene (AAF) on hepatocyte proliferation during the growth cycle; on the initiation of hepatocyte DNA synthesis in quiescent cultures; and, on hepatocyte DNA replication following the initiation of DNA synthesis. Scatchard analyses were used to identify the pharmacologic properties of radiolabeled AAF metabolite binding to hepatocyte macromolecules. Two classes of growth cycle-dependent AAF metabolite binding sites-a high-affinity low-capacity site (designated Site I) and a low-affinity high-capacity site (designated Site II)-associated with two spatially distinct classes of macromolecular targets, were revealed. Based upon radiolabeled AAF metabolite binding to purified hepatocyte genomic DNA or to DNA, RNA, proteins, and lipids from isolated nuclei, Site IDAY 4 targets (KD[APPARENT] approximately 2-4x10-6 M and BMAX[APPARENT] approximately 6 pmol/106 cells/24 h) were consistent with genomic DNA; and with AAF metabolized by a nuclear cytochrome P450. Based upon radiolabeled AAF binding to total cellular lysates, Site IIDAY 4 targets (KD[APPARENT] approximately 1.5x10-3 M and BMAX[APPARENT] approximately 350 pmol/106 cells/24 h) were consistent with cytoplasmic proteins; and with AAF metabolized by cytoplasmic cytochrome P450s. DNA synthesis was not inhibited by concentrations of AAF that saturated DNA binding in the neighborhood of the Site I KD. Instead, hepatocyte DNA synthesis inhibition required higher concentrations of AAF approaching the Site II KD. These observations raise the possibility that carcinogenic DNA adducts derived from AAF metabolites form below concentrations of AAF that inhibit replicative and repair DNA synthesis.
N-Acetyl-2-Aminofluorene (AAF) Processing in Adult Rat Hepatocytes in Primary Culture Occurs by High-Affinity Low-Velocity and Low-Affinity High-Velocity AAF Metabolite-Forming Systems.[Pubmed:29319795]
Toxicol Sci. 2018 May 1;163(1):26-34.
N-acetyl-2-Aminofluorene (AAF) is a procarcinogen used widely in physiological investigations of chemical hepatocarcinogenesis. Its metabolic pathways have been described extensively, yet little is known about its biochemical processing, growth cycle expression, and pharmacological properties inside living hepatocytes-the principal cellular targets of this hepatocarcinogen. In this report, primary monolayer adult rat hepatocyte cultures and high specific-activity [ring G-3 H]-N-acetyl-2-Aminofluorene were used to extend previous observations of metabolic activation of AAF by highly differentiated, proliferation-competent hepatocytes in long-term cultures. AAF metabolism proceeded by zero-order kinetics. Hepatocytes processed significant amounts of procarcinogen ( approximately 12 mug AAF/106 cells/day). Five ring-hydroxylated and one deacetylated species of AAF were secreted into the culture media. Extracellular metabolite levels varied during the growth cycle (days 0-13), but their rank quantitative order was time invariant: 5-OH-AAF > 7-OH-AAF > 3-OH-AAF > N-OH-AAF > aminofluorene (AF) > 1-OH-AAF. Lineweaver-Burk analyses revealed two principal classes of metabolism: System I (high-affinity and low-velocity), Km[APPARENT] = 1.64 x 10-7 M and VMAX[APPARENT] = 0.1 nmol/106 cells/day and System II (low-affinity and high-velocity), Km[APPARENT] = 3.25 x 10-5 M and VMAX[APPARENT] = 1000 nmol/106 cells/day. A third system of metabolism of AAF to AF, with Km[APPARENT] and VMAX[APPARENT] constants of 9.6 x 10-5 M and 4.7 nmol/106 cells/day, was also observed. Evidence provided in this report and its companion paper suggests selective roles and intracellular locations for System I- and System II-mediated AAF metabolite formation during hepatocarcinogenesis, although some of the molecules and mechanisms responsible for multi-system processing remain to be fully defined.